Recombinant Mouse IL-23 (carrier-free)

Product Details

Source

The mouse IL-23 consists of two subunits linked via a disulphide bond: P19 (Accession# NM_031252: Met1-Ala 196) and P40 (Accession# NM_008352 : Met Met1-Ser 335). Mouse IL-23 was expressed in insect cells.

Molecular Mass

The total predicted molecular weight is 55.4 kD. The non-reduced protein migrates at approximately 60 kD and the DTT-reduced protein produces two bands at approximately 19 kD (Leu 20-Ala 196) and 40 kD (Met 23-Ser 335) by SDS-PAGE.

Purity

Purity is >95%, as determined by Coomassie stained SDS-PAGE.

Formulation

0.22 µm filtered protein solution is in PBS

Endotoxin Level

Less than 0.01 ng per µg cytokine as determined by the LAL method.

Preparation

For maximum results, quick spin vial prior to opening. Stock solutions should be prepared at no less than 10 µg/mL in sterile buffer containing carrier protein such as 1% BSA or HSA or 10% FBS.

Concentration

10 and 25 µg sizes are bottled at 400 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.

Storage & Handling

Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.

Activity

ED₅₀ ≤1.5 ng/ml, corresponding to a specific activity of ≥0.66 x 10⁶ units/mg, as determined by mouse splenocytes IL-17A secretion induced by mIL-23 in a dose dependent manner.

Application

Bioassay

Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Get a 50% discount on this product when purchased in our Activation Bundles. Restrictions apply. Learn more…

Product Citations

1. Puleston DJ, et al. 2021. Cell. 184:4186. PubMed
2. Liu W, et al. 2022. Stem Cells Int. 2022:1052166. PubMed
3. Guo H, et al. 2022. Biomaterials. 283:121441. PubMed
4. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
5. Wang Y, et al. 2023. iScience. 26:106630. PubMed
6. Vereertbrugghen A, et al. 2023. J Neuroinflammation. 20:120. PubMed
7. Ando N, et al. 2015. J Invest Dermatol. . PubMed
8. Li W, et al. 2019. Front Immunol. 10:833. PubMed
9. Angiari S, et al. 2020. Cell Metab. 31:391. PubMed
10. Jia X, et al. 2021. Front Cell Dev Biol. 9:685522. PubMed
11. Martínez‐López M et al. 2019. Immunity. 50(2):446-461 . PubMed
12. Cai Y, et al. 2019. Cell Rep. 27:3034. PubMed
13. Zhang Y, et al. 2020. Aging (Albany NY). 12:13354. PubMed
14. Becker W, et al. 2021. J Crohns Colitis. 15:1032. PubMed
15. Barone F, et al. 2015. Proc Natl Acad Sci U S A. 112: 11024-11029. PubMed
16. Ji J, et al. 2021. Front Immunol. 12:787565. PubMed
17. Zeis P, et al. 2020. Immunity. 53:775. PubMed
18. Wu B, et al. 2021. Immunity. 54(2):308-323.e6. PubMed
19. Minns D, et al. 2021. Nat Commun. 12:1285. PubMed
20. Kaushik DK, et al. 2019. J Clin Invest. 130. PubMed
21. Smith KJ, et al. 2022. PLoS Biol. 20:e3001554. PubMed
22. Jin J, et al. 2020. Cell Reports. 30(12):4124-4136. PubMed
23. Li H, et al. 2019. Cancer Res. 79:2167. PubMed
24. Cho JJ, et al. 2019. Nat Commun. 10:701. PubMed
25. Hao L, et al. 2021. Br J Pharmacol. 178:4726. PubMed
26. Shin B, et al. 2020. Cell Rep. 1898:30. PubMed
27. Luo X, et al. 2021. Neuron. 109:2691. PubMed
28. Le A, et al. 2021. Front Immunol. 11:604785. PubMed
29. Xu K, et al. 2021. STAR Protoc. 2:100757. PubMed

RRID

AB_10663413 (BioLegend Cat. No. 589002)

Antigen Details

Structure

Heterodimer

Distribution

IL-23 is highly expressed by activated dendritic cells, macrophages, and epidermal Langerhans cells.

Function

IL-23 promotes Th17 responses in vivo, and it is important for the survival and population expansion of Th17 cells. IL-23 induces proliferation of memory T cells and the induction of IL-17A and IL-17F in these cells. IL-23 induces the secretion of IL-17, IL-17F, IL-6, and TNFα in Th17 cells. In conjunction with IL-1, IL-23 is sufficient to induce naïve human T cells to produce IL-17A, IL-17F, IL-22, IL-26, IFN-γ CCL20/MIP-3α and the transcription factor RORγt. PGE2 favors the production of IL-23 and inhibit IL-12 in dendritic cells. PGE2 synergizes with IL-23 in expanding Th17 cells from purified memory CD4+ T cells activated in the absence of accessory cells. IL-23 induces IFN-γ production from T cells treated with PHA. In addition, IL-23 plays a key role in the pathogenesis of autoimmune and chronic inflammatory disorders. This role is supported by the identification of IL-23 receptor (IL-23R) susceptibility alleles associated with inflammatory bowel disease, psoriasis, and ankylosing spondylitis.

Ligand/Receptor

IL-23 binds to L-12Rb1 and IL-23R

Cell Targets

Memory T cells, Th17 cells, Inflammatory macrophages, NK cells, dendritic cells, and monocytes.

Biology Area

Immunology, Stem Cells

Molecular Family

Cytokines/Chemokines

Antigen References

1. Oppmann B, et al. 2000. Immunity 13:715.
2. Aggarwal S, et al. 2003. J. Biol. Chem. 278:1910.
3. Piskin G, et al. 2006. J. Immunol. 176:1908.
4. Ivanov II, et al. 2006. Cell 126:1121.
5. McGeachy MJ, et al. 2007. Nat. Immunol. 8:1390.
6. Wilson NJ, et al. 2007. Nat. Immunol. 8:950.
7. Bonifac B, et al. 2008. Immunol. Rev. 226:132.
8. Chizzolini C, et al. 2008. Blood 112:3696.
9. Buonocore S, et al. 2010. Nature 464:1371.

Gene ID

16160 View all products for this Gene ID 83430 View all products for this Gene ID

UniProt

View information about IL-23 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Pages & Pathways

Related FAQs

Why choose BioLegend recombinant proteins?

     • Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
     • Greater than 95% Purity or higher, tested on every lot of product.
     • 100% Satisfaction Guarantee for quality performance, stability, and consistency.
     • Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
     • Bulk and customization available. Contact us.
     • Learn more about our Recombinant Proteins.

How does the activity of your recombinant proteins compare to competitors?

We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!

What is the specific activity or ED50 of my recombinant protein?

The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.

Have your recombinants been tested for stability?

Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.

Does specific activity of a recombinant protein vary between lots?

Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.

How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?

Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)

Certificate of Analysis